It is our pleasure that Pearl Fong, our vice president, was invited to have a speech in SNU BIO-MAX International Conference 2018 which is held at Seoul National University on November 27, 2018.
In the speech, Pearl shared the experience that Mycenax has the unique platform ‘’MBIFastTM
’’ which could shorten the process development timeline and improve the product quality for the therapeutic monoclonal antibody.
Mentioned in the speech, Mycenax’s efforts for our customers for continuous innovation never cease, as we always seek “new evolution” of technologies. “What do drug developers care most when it comes to production processes? “ Pearl asked. The answers are simple – time, quality, and cost – and our solutions make addressing those needs easier than ever!
In the conference, we provided the insight of the market trend and the R&D technology to the experts in Korea. We not only increase our brand awareness worldwide but also show our strengths that meet international standards and regulations.